as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹3,050.6
Change
+150.7 (5.2%)
Open
₹2,878.0
Prev. Close
₹2,899.9
Day High
₹3,127.8
Day Low
₹2,863.5
Volume Analysis
Traded
111,001
Delivered
54,842
Delivery %
49.41%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Trading within 3% of its 52-week high (₹3130.0)
- •Strong operating margin (21.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,428.74 | ₹3,278.27 | ₹3,164.44 | ₹3,013.97 | ₹2,900.14 | ₹2,749.67 | ₹2,635.84 |
| Fibonacci | ₹3,278.27 | ₹3,177.31 | ₹3,114.93 | ₹3,013.97 | ₹2,913.01 | ₹2,850.63 | ₹2,749.67 |
| Camarilla | ₹3,123.28 | ₹3,099.06 | ₹3,074.83 | ₹3,013.97 | ₹3,026.37 | ₹3,002.15 | ₹2,977.92 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+31.91%
1 Week
+10.52%
1 Month
+20.22%
3 Months
+33.07%
6 Months
+62.47%
1 Year
+32.34%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹757.29
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.06%
Net margin 16.35% × asset turnover 0.89x × equity multiplier 1.31x
Company Overview
Sector
Healthcare
Market Cap
₹5,045 Cr
P/E (TTM)
43.2
ROE
19.3%
Book Value
₹366.0
Face Value
₹8.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Rpg Life Sciences Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Financial Strength (100/100), while Valuation (5/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹3130.0); strong operating margin (21.0%).
TopFund Score — Fundamentals Quality
67/100 — GoodData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- −Stock is trading at 8.33 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
RPG Active Pharma approved merger of Actis Generics on September 25, 2026, pending NCLT and shareholder approvals.
RPGAP completed Actis Generics acquisition on September 24, 2026; Actis became RPG Life Sciences subsidiary.
RPG Life Sciences clarified no undisclosed event behind recent volume increase.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| Expenses + | 124 | 118 | 133 | 143 | 140 | 144 | 152 |
| Operating Profit | 49 | 25 | 35 | 39 | 40 | 33 | 43 |
| OPM % | 28.0% | 18.0% | 21.0% | 21.0% | 22.0% | 19.0% | 22.0% |
| Other Income + | 3 | 115 | 5 | 16 | -5 | 14 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 47 | 135 | 35 | 49 | 29 | 40 | 41 |
| Tax % | 26.0% | 13.0% | 26.0% | 25.0% | 24.0% | 26.0% | 26.0% |
| Net Profit + | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS in Rs | 21 | 71 | 16 | 22 | 13 | 18 | 19 |
| Raw PDF | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales + | 653 | 708 | 734 |
| Expenses + | 493 | 560 | 579 |
| Operating Profit | 161 | 148 | 155 |
| OPM % | 25.0% | 21.0% | 21.0% |
| Other Income + | 95 | 29 | 29 |
| Interest | 2 | 2 | 1 |
| Depreciation | 21 | 21 | 22 |
| Profit before tax | 233 | 154 | 160 |
| Tax % | 21.0% | 25.0% | — |
| Net Profit + | 183 | 115 | 120 |
| EPS in Rs | 111 | 70 | 72 |
| Dividend Payout % | 22.0% | 34.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Reserves | 517 | 592 |
| Borrowings + | 0 | 20 |
| Other Liabilities + | 127 | 168 |
| Total Liabilities | 658 | 793 |
| Fixed Assets + | 172 | 197 |
| CWIP | 16 | 23 |
| Investments | 127 | 85 |
| Other Assets + | 343 | 488 |
| Total Assets | 658 | 793 |
| Equity Capital | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity + | 78 | 56 |
| Cash from Investing Activity + | -42 | 86 |
| Cash from Financing Activity + | -27 | -21 |
| Net Cash Flow | 9 | 122 |
| CFO/OP | 81 | 63 |
| Free Cash Flow | 151 | -9 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 25.15% | 24.85% | 24.12% | 23.44% | 20.4% | 19.7% | 19.46% | 19.22% | 19.23% | 19.01% | 18.72% | 17.42% |
| Promoters | 72.82% | 72.82% | 72.82% | 72.82% | 72.82% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| FII | 0.46% | 0.56% | 0.9% | 1.15% | 1.35% | 1.3% | 1.46% | 1.35% | 1.11% | 1.0% | 0.87% | 0.95% |
| DII | 1.57% | 1.77% | 2.16% | 2.61% | 5.45% | 6.06% | 6.14% | 6.49% | 6.7% | 7.04% | 7.45% | 8.68% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Rpg Life Sciences Ltd (this stock) | 5,045 | 43.2 | 8.34 | 19.3% |
| Zota Health Care Limited | 4,696 | — | 6.78 | -15.0% |
| Gujarat Themis Biosyn Ltd | 5,442 | 112.0 | — | — |
| Fdc Limited | 5,641 | 18.3 | 2.26 | 11.2% |
| Sms Pharmaceuticals Ltd. | 4,448 | 43.4 | 5.66 | 14.3% |
| Gufic Biosciences Ltd. | 4,237 | 57.7 | 6.37 | 10.1% |
| Artemis Med Service Ltd | 5,917 | 51.0 | 6.34 | 12.0% |
Which Mutual Funds Hold Rpg Life Sciences Ltd?
Frequently Asked Questions about Rpg Life Sciences Ltd
Rpg Life Sciences Ltd (RPGLIFE) closed at ₹3,050.6 on NSE on 25 September 2026, up 150.7 (5.2%) from the previous close.
Rpg Life Sciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol RPGLIFE.
Rpg Life Sciences Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 43.2.
Rpg Life Sciences Ltd has a dividend yield of 0.79%.
Rpg Life Sciences Ltd's 52-week high is ₹3,130.0 and its 52-week low is ₹1,731.0.
Rpg Life Sciences Ltd has a market capitalisation of ₹5,045 crore.
Rpg Life Sciences Ltd has a TopFund Quality Score of 67/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Rpg Life Sciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.